A phase 1/1b dose escalation study of abemaciclib and olaparib for recurrent platinum-resistant ovarian cancer

This study is being done to answer the following question: Can abemaciclib and olaparib be taken safely together in ovarian cancer that has come back? We are asking you to take part in this research study because you have ovarian cancer that has come back. We are trying to determine whether abemaciclib and olaparib can be taken safely and tolerably together in ovarian cancer that has come back.

Are you Eligible? (Inclusion Criteria)

• Must have ovarian cancer that has come back within 6 months of last dose of treatment.
• Must have received 1-3 prior treatment regimens.
• Must have lesions seen on CT scan or MRI.